 |
| 삼성바이오로직스 인천 송도 공장 (사진=삼성바이오로직스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] It was belatedly confirmed that a U.S. pharmaceutical company filed a patent infringement suit with Samsung BioLogics and others.
According to legal circles on the 17th, Regeneron Pharmaceuticals (REGN) filed a lawsuit with the Seoul Central District Court in January against Samsung BioLogics and its subsidiary Epis for "prohibition of patent infringement and prevention."
The reason for the lawsuit is that Regeneron has violated some patents related to blockbuster eye disease treatments acquired by the Korean Intellectual Property Office, and cloned drugs under development by Samsung Bioepis.
Sales of eye disease treatment Eylea in the first quarter were $2.28 billion, less than analyst estimates of $2.43 billion, according to Regeneron data.
Nevertheless, Eylea generates about 13 trillion won in sales from single drug sales around the world.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
